摘要
目的观察探讨晚期非小细胞肺癌患者血清转化生长因子β1(TGF-β1)和血管内皮生长因子(VEGF)的表达与临床疗效的相关性。方法选取2012年我院晚期非小细胞肺癌化疗疗效达临床获益(CR+PR+SD)的患者30例,酶联免疫吸附法(ELISA)检测其治疗前、化疗2周期至4周期后疗效达临床获益时,以及患者疾病进展时血清TGF-β1和VEGF水平。将不同时期的TGF-β1和VEGF水平进行比较。结果患者化疗疗效达临床获益时的血清TGF-β1和VEGF水平较治疗前下降,无统计学差异;在疾病进展时血清TGF-β1和VEGF水平较临床获益时明显增高,有统计学差异。结论晚期非小细胞肺癌患者血清TGF-β1和VEGF的表达与临床疗效相关,可作为患者疗效评价以及疾病监测的指标。
Objective To measure serum levels of TGF-β1 and VEGF in patients with advanced non-small cell hang cancer （NSCLC） and determine their clinical efficacy. Methods Serum levels of TGF-β1 and VEGF were determined by＇ELISA in 30 cases of advanced NSCLC, different period serum levels were compared of prior therapy, clinical benefit and progressive disease. Results Serum levels of TGF-β1 and VEGF in patients with the clinical benefit were lower in prior therapy. Serum levels of TGF-β1 and VEGF in patients with progressive disease period were significantly higher than in the clinical benefit. （P〈0.01）. Conclusion Serum levels of TGF-β1 and VEGF in advanced NSCLC patients were positively correlated their clinical efficacy, may be useful in estimating the efficacy and detection the development and for transfer of NSCLC.
出处
《疾病监测与控制》
2014年第4期210-211,共2页
Journal of Diseases Monitor and Control
